Search results for "Living donor"

showing 10 items of 46 documents

A New Systematic Classification of Peripheral Anatomy of the Right Hepatic Duct: Experience From Adult Live Liver Donor Transplantation

2008

Abstract Objective The peripheral intrahepatic biliary anatomy, especially at the sectorial level on the right side, has not been adequately described. The purpose of our study was to systematically describe this complex anatomy in clinically applicable fashion. Patients and Methods We analyzed three-dimensional computed tomography (CT) imaging reconstructions of 139 potential living liver donors evaluated at our institution between January 2003 and June 2007. Results Eighty-nine (64%) donors had a normal right bile duct sectorial anatomy. In the other 50/139 (36%) cases, we observed abnormal sectorial branching patterns, with 45/50 abnormalities as trifurcations, whereas the remaining ones…

Adultmedicine.medical_treatmentHepatic Duct CommonLiver transplantationAnastomosisFunctional LateralityCholangiographyImage Processing Computer-AssistedLiving DonorsmedicineHumansSurvivorsTransplantationmedicine.diagnostic_testBile ductbusiness.industryGallbladderAnastomosis SurgicalGallbladderAnatomyLobeCholecystographyLiver TransplantationSurvival RateTransplantationmedicine.anatomical_structureSurgeryBile DuctsHepatectomyTomography X-Ray ComputedbusinessCholangiographyTransplantation Proceedings
researchProduct

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine mic…

2006

The LIS2T study was an open-label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA-ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood level [predose]) C0 to compare efficacy and safety at 3 and 6 months and to evaluate patient status at 12 months. All patients received steroids with or without azathioprine. At 12 months, 85% of CsA-ME patients and 86% of tacrolimus patients survived with a functioning graft (P not significant). Efficacy was similar in deceased- and living-donor recipients. Significantly fewer hepatitis C–positive pati…

Graft RejectionMaleTime Factorsmedicine.medical_treatmentTACROLIMUSAzathioprineHepacivirusHEPATITIS-CLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compoundLiving DonorsLongitudinal StudiesC-2IMMUNOSUPPRESSIONHEPATITIS-C DIABETES-MELLITUS C-2 REPLICATION RECURRENCE SURVIVALGraft SurvivalHepatitis CTreatment Outcomesurgical procedures operativeCreatinineSURVIVALEmulsionsFemaleSteroidsImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyHepatitis C virusRenal functionRANDOMIZED STUDYAge DistributionInternal medicinemedicineDiabetes MellitusHumansHypoglycemic AgentsRECURRENCEMonitoring PhysiologicHepatitisTransplantationCreatinineHepatologybusiness.industryLIVER TRANSPLANTATIONDIABETES-MELLITUSmedicine.diseaseSurvival AnalysisTacrolimusSurgerychemistryREPLICATIONCYCLOSPORINESurgerybusinessFollow-Up Studies
researchProduct

Metabolomics discloses donor liver biomarkers associated with early allograft dysfunction

2014

Background & Aims Early allograft dysfunction (EAD) dramatically influences graft and patient outcome after orthotopic liver transplantation and its incidence is strongly determined by donor liver quality. Nevertheless, objective biomarkers, which can assess graft quality and anticipate organ function, are still lacking. This study aims to investigate whether there is a preoperative donor liver metabolomic biosignature associated with EAD. Methods A comprehensive metabolomic profiling of 124 donor liver biopsies collected before transplantation was performed by mass spectrometry coupled to liquid chromatography. Donor liver grafts were classified into two groups: showing EAD and immediate g…

Graft RejectionMalemedicine.medical_specialtyOrthotopic liver transplantationmedicine.drug_classBiopsyHistidine MetabolismGastroenterologyBile Acids and SaltsModel for End-Stage Liver DiseaseMetabolomicsPredictive Value of TestsRisk FactorsInternal medicineLipidomicsmedicineHumansMetabolomicsHistidinePhospholipidsHepatologyBile acidbusiness.industryMiddle AgedAllograftsTissue DonorsLiver TransplantationSphingomyelinsTransplantationLiverBiochemistryFemaleLysophospholipidsbusinessLiving donor liver transplantationBiomarkersJournal of Hepatology
researchProduct

Donor/recipient algorithm for management of the middle hepatic vein in right graft live donor liver transplantation

2010

Abstract Background The aim of this study was to delineate an algorithm for donor and recipient criteria and middle hepatic vein (MHV) management in right-graft live-donor liver transplantation (LDLT) on the basis of computerized 3-dimensional computed tomographic image analysis. Methods Data on 94 consecutive right-graft LDLTs were prospectively collected. Graft and remnant data for the first 23 cases were retrospectively evaluated by means of 3-dimensional computed tomographic reconstructions, and on the basis of that preliminary series, a graft selection algorithm using 3 parameters—hepatic vein dominance classification, graft and remnant graft volume/body weight ratios, and congestion v…

Graft RejectionMalemedicine.medical_specialtyTissue and Organ ProcurementLive donormedicine.medical_treatmentHepatic VeinsLiver transplantationliverBody weightRisk AssessmentPreoperative careComputed tomographicCohort StudiesImaging Three-DimensionalPostoperative ComplicationsPreoperative CareLiving DonorsmedicineGraft selectionHepatectomyHumansProspective StudiesAnalysis of VarianceSmall for size syndromebusiness.industryPatient SelectionGraft SurvivalGeneral MedicineLiver TransplantationSurgeryTreatment Outcomesurgical procedures operativeMathematikFemaleSurgeryHepatectomyTomography X-Ray ComputedbusinessAlgorithmAlgorithmsFollow-Up StudiesLiver CirculationThe American Journal of Surgery
researchProduct

Preclinical report on allogeneic uterus transplantation in non-human primates

2013

Study question Is it possible to perform allogeneic uterus transplantation (UTx) with a donation from a live donor in a non-human primate species and what immunosuppression is needed to prevent rejection? Summary answer Allogeneic UTx in the baboon is a donor- and recipient-safe surgical procedure; immunosuppression with induction therapy and a triple protocol should be used. What is known already UTx may become a treatment for absolute uterine factor infertility. Autologous UTx models have been developed in non-human primates with reports on long-term survival of the uterine grafts. STUDY DESIGN, SIZEAND DURATION: This experimental study included 18 female baboons as uterus donors and 18 f…

Graft Rejectionmedicine.medical_specialtymedicine.medical_treatmentUterusTacrolimusMaintenance ChemotherapyAdrenal Cortex Hormonesmedicine.arteryUterus transplantationmedicineLiving DonorsAnimalsTransplantation HomologousExternal iliac veinAntilymphocyte SerumImmunosuppression TherapyUterine DiseasesHysterectomybusiness.industryRehabilitationGraft SurvivalUterusObstetrics and GynecologyImmunosuppressionInduction ChemotherapyMycophenolic AcidInternal iliac arteryTacrolimusSurgeryTransplantationDisease Models Animalmedicine.anatomical_structureReproductive MedicineFeasibility StudiesDrug Therapy CombinationFemalebusinessInfertility FemalePapio
researchProduct

Die Sicherheit des Lebendnierenspenders – Das Deutsche Lebendspende Register SOLKID-GNR – Entstehung und Struktur eines nationalen Registers in der V…

2021

ZusammenfassungIm Deutschen Lebendspende Register SOLKID-GNR (Safety of the Living Kidney Donor – The German National Register) werden medizinische und psychosoziale Daten zum Outcome von Lebendnierenspender erhoben. Die prospektive Datenerhebung ermöglicht erstmals in Deutschland eine wissenschaftlich fundierte Langzeitanalyse, wie sich eine Lebendnierenspende auf die psychische und physische Gesundheit von Lebendnierenspendern auswirkt. Dies trägt direkt zu einer Verbesserung der Information und Versorgung der Lebendnierenspender bei.

Gynecologymedicine.medical_specialtyPolitical sciencePublic Health Environmental and Occupational HealthmedicineLiving donorDas Gesundheitswesen
researchProduct

Human uterus transplantation in focus.

2016

Introduction Uterus transplantation (UTx) is introduced as the first treatment for absolute uterine factor infertility (AUFI), affecting 1:500 fertile aged women. This review presents potential patients, research and human UTx cases. Sources of data Published articles and our research experience. Areas of agreement The first UTx live births in 2014 established UTx as a possible treatment for AUFI. This was proceeded by 15 years of systematic research. Areas of controversy Is a deceased donor UTx as effective as the proven successful live donor UTx?. Growing points Human UTx trials will accumulate data on risks, effectiveness and long-term consequences for donors, recipients and children. Th…

Infertilitymedicine.medical_specialty03 medical and health sciences0302 clinical medicineQuality of lifeUterus transplantationmedicineLiving DonorsAnimalsHumansEthics Medical030219 obstetrics & reproductive medicineObstetricsbusiness.industryFemale infertilityUterusGeneral Medicinemedicine.diseaseChild developmentTransplantationDisease Models Animal030220 oncology & carcinogenesisFamily medicineObservational studyFemalebusinessLive birthInfertility FemaleBritish medical bulletin
researchProduct

Ethics of uterus transplantation with live donors.

2014

Infertilitymedicine.medical_specialtyReproductive Techniques Assistedmedia_common.quotation_subjectTreatment outcomeMEDLINEFertilityRisk AssessmentPregnancyRisk FactorsUterus transplantationLiving DonorsMedicineHumansProgram Developmentmedia_commonGynecologyPregnancybusiness.industryPatient SelectionUterusObstetrics and GynecologyOrgan Transplantationmedicine.diseaseFertilityTreatment OutcomeReproductive MedicineProgram developmentFemalebusinessRisk assessmentInfertility FemaleFertility and sterility
researchProduct

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myel…

2007

Abstract The Dutch-Belgian Hemato-Oncology Cooperative Group and the Swiss Group for Clinical Cancer Research (HOVON-SAKK) collaborative study group evaluated outcome of patients (pts) with acute myeloid leukemia (AML) in first remission (CR1) entered in 3 consecutive studies according to a donor versus no-donor comparison. Between 1987 and 2004, 2287 pts were entered in these studies of whom 1032 pts (45%) without FAB M3 or t(15;17) were in CR1 after 2 cycles of chemotherapy, received consolidation treatment, and were younger than 55 years of age and therefore eligible for allogeneic hematopoietic stem cell transplantation (allo-SCT). An HLA-identical sibling donor was available for 326 pt…

MaleMyeloidTransplantation Conditioningmedicine.medical_treatmentHematopoietic stem cell transplantationBiochemistryGastroenterologyRecurrenceRisk FactorsUNRELATED DONORSLiving DonorsMedicineTOTAL-BODYACUTE MYELOGENOUS LEUKEMIAHistocompatibility TestingAge FactorsHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyCOLONY-STIMULATING FACTORMiddle AgedChemotherapy regimenSurvival RateLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureFemalePOSTREMISSION THERAPYAdultmedicine.medical_specialtyAcute myeloblastic leukemiaAdolescentImmunologymacromolecular substancesDisease-Free SurvivalMeta-Analysis as TopicInternal medicineotorhinolaryngologic diseasesHumansTransplantation HomologousSurvival rateRetrospective StudiesEUROPEAN GROUPbusiness.industryACUTE MYELOBLASTIC-LEUKEMIACell Biologymedicine.diseaseBONE-MARROW-TRANSPLANTATIONINTENSIVE CHEMOTHERAPYSurgeryTransplantationAML-10 TRIALbusinessFollow-Up StudiesBlood
researchProduct

Adult to Adult Living Donor Liver Transplantation in Recipients with Low MELD: A Strategy Intended to Overcome Donor Shortage

2020

Recent series have demonstrated advantages of living donor over deceased donor liver transplantation, with particular benefit for those with low model for end-stage liver disease score. The logic underlying the transplantation of patients before they become too sick is intuitive. It reduces mortality and drop outs from the waiting list and makes transplant surgery less demanding. Those principles have to be balanced with donor safety and transplant benefit for the recipient avoiding early, futile transplantation. The authors report a case of adult to adult right lobe living donor liver transplantation performed for a recipient affected by primary biliary cirrhosis with MELD score of 15, in …

MalePhysiologymedicine.medical_treatmentLiver transplantationSeverity of Illness IndexLiver diseasePostoperative Complications0302 clinical medicinePrimary biliary cirrhosisTransplant surgeryLiving DonorsLiver Transplantation.Liver resectionLiver Cirrhosis BiliaryGastroenterologyCone-Beam Computed TomographyMiddle AgedTreatment Outcomesurgical procedures operativeItalyLiver030220 oncology & carcinogenesisFemaleRisk Adjustment030211 gastroenterology & hepatologyLiving donor liver transplantationHumanAdultmedicine.medical_specialtyTissue and Organ ProcurementClinical Decision-MakingTime-to-TreatmentEnd Stage Liver Disease03 medical and health sciencesInternal medicineSeverity of illnessmedicineHepatectomyHumansIntensive care medicineLiver transplantationbusiness.industryLiving donor liver transplantationHepatologymedicine.diseasePleural EffusionTransplantationSurgeryPostoperative Complicationbusiness
researchProduct